Cancer-selective gene therapy company Tocagen has become the third company to get accepted on the European Medicines Agency’s priority medicines (PRIME) scheme for an investigational drug for brain cancer.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?